DJIA 18,030.21 6.04 0.03%
NASDAQ 4,773.47 8.05 0.17%
S&P 500 2,081.88 -0.29 -0.01%
market minute promo

5.98 0.01 (0.17%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

OREX $5.98 0.17%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.95
Previous Close $5.97
Daily Range $5.73 - $6.00
52-Week Range $3.11 - $7.82
Market Cap $736.5M
P/E Ratio -11.06
Dividend (Yield) $0.00 (0.0%)
Volume 997,564
Average Daily Volume 3,803,668
Current FY EPS -$0.42





Orexigen Therapeutics, Inc. (OREX) Description

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity. Website:

News & Commentary

Buying These 3 Stocks Is Like Making a Bet in a Burning House

Aegerion Pharmaceuticals, MannKind Corp., and VIVUS, Inc. have all attracted short sellers in droves this year. With each company facing serious headwinds, should investors avoid these struggling biotechs?

Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst Blog

Novo Nordisk Enters Anti-Obesity Space With New FDA Approval

Orexigen's Obesity Drug Mysimba Gets CHMP Nod - Analyst Blog

Contrave Prescriptions Still Rising In A Down Week

Orexigen - Contrave Script Numbers Remain Impressive

Orexigen Therapeutics (OREX) Stock: Weak On High Volume Today

New Obesity Drug Available Soon

Orexigen is close to getting Mysimba on the market in Europe.

Arena And Vivus Investors Need To Grasp Implications Of Orexigen

Orexigen Therapeutics Gains On Diet Pill Nod From European Committee

See More OREX News...

OREX's Top Competitors

OREX $5.98 (0.17%)
Current stock: OREX
AMGN $160.67 (2.00%)
Current stock: AMGN
GILD $91.15 (1.90%)
Current stock: GILD
BIIB $340.89 (1.53%)
Current stock: BIIB